Addex Therapeutics (NASDAQ:ADXN) Shares Up 4% – Here’s What Happened

Addex Therapeutics Ltd. Sponsored ADR (NASDAQ:ADXN)’s stock price traded up 4% during trading on Friday . The company traded as high as $7.03 and last traded at $6.45. 21,353 shares traded hands during mid-day trading, an increase of 1,072% from the average session volume of 1,821 shares. The stock had previously closed at $6.20.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Addex Therapeutics in a research note on Wednesday, April 8th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, Addex Therapeutics has an average rating of “Sell”.

Addex Therapeutics Stock Up 4.0%

The company has a market cap of $7.93 million, a P/E ratio of -1.12 and a beta of 1.48. The business’s 50 day moving average is $6.73 and its 200 day moving average is $7.24.

About Addex Therapeutics

Addex Therapeutics SA is a clinical-stage biopharmaceutical company specializing in the discovery and development of small-molecule allosteric modulators for central nervous system disorders. Founded in 1999 and headquartered in Geneva, Switzerland, with a U.S. research presence in Cambridge, Massachusetts, the company focuses on targeting metabotropic glutamate (mGlu) receptors and GABAB receptors to address unmet medical needs in neurology and psychiatry.

The company’s lead candidate, dipraglurant (ADX48621), is an mGlu5 negative allosteric modulator in clinical development for levodopa-induced dyskinesia in Parkinson’s disease.